Literature DB >> 18660830

Superoxide from NADPH oxidase upregulates type 5 phosphodiesterase in human vascular smooth muscle cells: inhibition with iloprost and NONOate.

S Muzaffar1, N Shukla, M Bond, G B Sala-Newby, A C Newby, G D Angelini, J Y Jeremy.   

Abstract

BACKGROUND AND
PURPOSE: To determine whether there is an association between vascular NADPH oxidase (NOX), superoxide, the small GTPase Rac(1) and PDE type 5 (PDE5) in human vascular smooth muscle cell (hVSMCs). EXPERIMENTAL APPROACH: hVSMCs were incubated with xanthine-xanthine oxidase (X-XO; a superoxide generating system) or the thromboxane A(2) analogue, U46619 (+/-superoxide dismutase (SOD) or apocynin) for 16 h. The expression of PDE5 and NOX-1 was assessed using Western blotting and superoxide measured. The role of Rac(1) in superoxide generation was assessed by overexpressing either the dominant-negative or constitutively active Rac isoforms. The effects of iloprost, DETA-NONOate and the Rho-kinase inhibitor, Y27632, on PDE5 and NOX-1 expression were also studied. KEY
RESULTS: Following 16 h incubation, U46619 and X-XO promoted the expression of PDE5 and NOX-1, an effect blocked by SOD or apocynin when co-incubated over the same time course. X-XO and U46619 both promoted the formation of superoxide. Overexpression of dominant-negative Rac(1) or addition of iloprost, DETA-NONOate or Y27632 completely blocked both superoxide release and PDE5 protein expression and activity. CONCLUSIONS AND IMPLICATIONS: These data demonstrate that superoxide derived from NOX upregulates the expression of PDE5 in human VSMCs. As PDE5 hydrolyses cyclic GMP, this effect may blunt the vasculoprotective actions of NO.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18660830      PMCID: PMC2597240          DOI: 10.1038/bjp.2008.300

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  33 in total

Review 1.  Nitric oxide and the proliferation of vascular smooth muscle cells.

Authors:  J Y Jeremy; D Rowe; A M Emsley; A C Newby
Journal:  Cardiovasc Res       Date:  1999-08-15       Impact factor: 10.787

Review 2.  Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology.

Authors:  K K Griendling; D Sorescu; B Lassègue; M Ushio-Fukai
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-10       Impact factor: 8.311

3.  Acute inhibition of superoxide formation and Rac1 activation by nitric oxide and iloprost in human vascular smooth muscle cells in response to the thromboxane A2 analogue, U46619.

Authors:  S Muzaffar; N Shukla; M Bond; G Sala-Newby; G D Angelini; A C Newby; J Y Jeremy
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2008-04-16       Impact factor: 4.006

4.  Superoxide auto-augments superoxide formation and upregulates gp91(phox) expression in porcine pulmonary artery endothelial cells: inhibition by iloprost.

Authors:  Saima Muzaffar; Nilima Shukla; Gianni D Angelini; Jamie Y Jeremy
Journal:  Eur J Pharmacol       Date:  2006-03-28       Impact factor: 4.432

Review 5.  The Rac and Rho hall of fame: a decade of hypertrophic signaling hits.

Authors:  Joan Heller Brown; Dominic P Del Re; Mark A Sussman
Journal:  Circ Res       Date:  2006-03-31       Impact factor: 17.367

Review 6.  Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress.

Authors:  H Cai; D G Harrison
Journal:  Circ Res       Date:  2000-11-10       Impact factor: 17.367

7.  Elongation factor-1 alpha is a novel substrate of rho-associated kinase.

Authors:  T Izawa; Y Fukata; T Kimura; A Iwamatsu; K Dohi; K Kaibuchi
Journal:  Biochem Biophys Res Commun       Date:  2000-11-11       Impact factor: 3.575

8.  RhoA/Rho-kinase contribute to the pathogenesis of diabetic renal disease.

Authors:  Fangfang Peng; Dongcheng Wu; Bo Gao; Alistair J Ingram; Baifang Zhang; Katherine Chorneyko; Rick McKenzie; Joan C Krepinsky
Journal:  Diabetes       Date:  2008-03-20       Impact factor: 9.461

9.  Rho GTPase/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells.

Authors:  Xiu-Fen Ming; Hema Viswambharan; Christine Barandier; Jean Ruffieux; Kozo Kaibuchi; Sandro Rusconi; Zhihong Yang
Journal:  Mol Cell Biol       Date:  2002-12       Impact factor: 4.272

10.  Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase.

Authors:  Masao Takemoto; Jianxin Sun; Junko Hiroki; Hiroaki Shimokawa; James K Liao
Journal:  Circulation       Date:  2002-07-02       Impact factor: 29.690

View more
  13 in total

Review 1.  cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action.

Authors:  Sharron H Francis; Jennifer L Busch; Jackie D Corbin; David Sibley
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

Review 2.  The role of genetic polymorphisms in antioxidant enzymes and potential antioxidant therapies in neonatal lung disease.

Authors:  Carlo Dani; Chiara Poggi
Journal:  Antioxid Redox Signal       Date:  2014-02-19       Impact factor: 8.401

3.  SOD and inhaled nitric oxide normalize phosphodiesterase 5 expression and activity in neonatal lambs with persistent pulmonary hypertension.

Authors:  Kathryn N Farrow; Satyan Lakshminrusimha; Lyubov Czech; Beezly S Groh; Sylvia F Gugino; Jonathan M Davis; James A Russell; Robin H Steinhorn
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-04-16       Impact factor: 5.464

4.  Brief hyperoxia increases mitochondrial oxidation and increases phosphodiesterase 5 activity in fetal pulmonary artery smooth muscle cells.

Authors:  Kathryn N Farrow; Keng Jin Lee; Marta Perez; Jacqueline M Schriewer; Stephen Wedgwood; Satyan Lakshminrusimha; Cody L Smith; Robin H Steinhorn; Paul T Schumacker
Journal:  Antioxid Redox Signal       Date:  2012-03-08       Impact factor: 8.401

5.  Mitochondrial oxidant stress increases PDE5 activity in persistent pulmonary hypertension of the newborn.

Authors:  Kathryn N Farrow; Stephen Wedgwood; Keng Jin Lee; Lyubov Czech; Sylvia F Gugino; Satyan Lakshminrusimha; Paul T Schumacker; Robin H Steinhorn
Journal:  Respir Physiol Neurobiol       Date:  2010-09-06       Impact factor: 1.931

6.  The NADPH oxidase inhibitor diphenyleneiodonium is also a potent inhibitor of cholinesterases and the internal Ca(2+) pump.

Authors:  T Tazzeo; F Worek; Lj Janssen
Journal:  Br J Pharmacol       Date:  2009-09-25       Impact factor: 8.739

Review 7.  Vascular endothelial dysfunction and pharmacological treatment.

Authors:  Jin Bo Su
Journal:  World J Cardiol       Date:  2015-11-26

Review 8.  Vascular endothelial dysfunction, a major mediator in diabetic cardiomyopathy.

Authors:  Maura Knapp; Xin Tu; Rongxue Wu
Journal:  Acta Pharmacol Sin       Date:  2018-06-04       Impact factor: 6.150

9.  Renin-angiotensin-aldosterone system genes and nonarteritic anterior ischemic optic neuropathy.

Authors:  Sofia Markoula; Sotirios Giannopoulos; Ioannis Asproudis; Charilaos Kostoulas; Alexios Nikas; Eleni Bagli; Athanassios P Kyritsis; Ioannis Georgiou
Journal:  Mol Vis       Date:  2011-05-06       Impact factor: 2.367

10.  Pediatric Pulmonary Hypertension: Definitions, Mechanisms, Diagnosis, and Treatment.

Authors:  Devashis Mukherjee; Girija G Konduri
Journal:  Compr Physiol       Date:  2021-06-30       Impact factor: 8.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.